BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 15, 2003
View Archived Issues
Neurocrine Biosciences Brings In $200M In Oversold Public Offering
Marching ahead with its non-benzodiazepine insomnia drug indiplon, Neurocrine Biosciences Inc. said it priced an offering of 3.75 million shares at $53 per share, for net proceeds of about $200 million. (BioWorld Today)
Read More
Tercica, Armed With Genentech Technology, Seeks $86.25M IPO
Read More
Ligand Gains $47M In Private Sale To Expand Commercial Activities
Read More
Alexion Raises $44 Million For Development Of Pipeline Drugs
Read More
Axonyx Placement Garners $25M For Second Phase III
Read More
Other News To Note
Read More